Business EconomyPosted at: Apr 18 2025 3:16PM


Zydus Medtech partners with Braile Biomedica to commercialise TAVI technology

Mumbai, Apr 18 (UNI) Zydus MedTech Private Limited, a wholly owned subsidiary of Zydus Lifesciences Limited on Friday entered into a strategic partnership with Braile Biomédica Indústria, Comércio e Representações Ltda., (Braile Biomedica) - an innovative cardiovascular device manufacturer based in Brazil - to exclusively commercialise its Transcatheter Aortic Valve Implantation (TAVI) technology across Europe, India, and other select markets.

It was a significant step in Zydus MedTech’s strategic expansion into the fast-growing interventional cardiology segment.
Dr Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., said “We stand united with Braile to improve patient outcomes and expand access to advanced, critical cardiovascular care globally. This innovative, cutting-edge technology will offer a minimally invasive approach that also supports faster recovery, reduced hospital stays, and greatly improved quality of life for patients.”
The global TAVI market, currently valued at over USD 6 billion, continues to witness strong growth driven by the increasing incidence of aortic stenosis and the rising demand for minimally invasive cardiac procedures.
Zydus MedTech, which is actively building its interventional cardiology portfolio, will introduce Braile Biomedica’s advanced balloon-expandable TAVI system to international markets, leveraging its commercial and regulatory expertise. Braile Biomedica - with a proven track record in cardiovascular innovation, particularly in Latin America - will manufacture and supply the product for these markets.
This agreement aligns with both companies’ shared commitment to delivering life-saving technologies to a broader patient population. The TAVI procedure is a recognized breakthrough in structural heart care, particularly for elderly patients or those at high surgical risk. By replacing the diseased aortic valve through a catheter-based approach - without the need for open-heart surgery - patients often experience significantly shorter recovery times and reduced procedural risks. The expansion of TAVI indications to all-risk patients has further accelerated its adoption.
UNI JS NV CS
Please log in to get detailed story.
Tags: #Zydus Medtech partners with Braile Biomedica to commercialise TAVI technology
More News

Manipur officials want more banks , assure land for financial activities

16 May 2025 | 8:40 PM

Imphal, May 16 (UNI) The 82nd State Level Bankers Committee for Manipur was held on Friday under the chairmanship of the state Chief Secretary, PK Singh.

see more..

Kottayam-Kochi rubber market rates

16 May 2025 | 7:15 PM

Kottayam, May 16(UNI) Following were the Rubber Market rates announced by the Rubber Board here today per quintal.

see more..
Rupee marginally up 2 paise against USD

Rupee marginally up 2 paise against USD

16 May 2025 | 6:41 PM

Mumbai, May 16 (UNI) The Rupee on Friday ended positive at 85.51, rising two paise against USD on fresh selling of US Dollar from foreign banks and importers, dealers at the Forex Market said.

see more..
Sensex falls 200 15 pts

Sensex falls 200 15 pts

16 May 2025 | 6:37 PM

Mumbai, May 16 (UNI) The BSE Sensex on Friday, the last trading day of the week ended weak at 82,330.59, down 200.15 pts amid profit booking in Technology, IT and Bankex stocks despite positive global cues.

see more..

BSE Sensex closes at 82,330 59, down 200 15 pts and Nifty at 25,019 80, falls 42 30 pts

16 May 2025 | 3:37 PM

UNI NV ARN.

see more..